HOGBERG; Marita
Patent Applications and Registrations
Patent applications and USPTO patent grants for HOGBERG; Marita.The latest application filed is for "novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer".
- HOGBERG; Marita - Tullinge SE
- Hogberg; Marita - Huddinge N/A SE
- Hogberg; Marita - Tulling SE
| Patent | Date |
|---|---|
| Novel Combinations Of A Tubulin Polymerization Inhibitor And A Poly (adp-ribose) Polymerase (parp) Inhibitor For Use In The Treatment Of Cancer App 20210052583 - HOGBERG; Marita ; et al. | 2021-02-25 |
| 4-(indolyl Or Benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines Useful For The Treatment Of Cancer App 20150252026 - Johansson; Tommy ; et al. | 2015-09-10 |
| 4-indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines Useful For The Treatment Of Cancer App 20150225374 - Johansson; Tommy ; et al. | 2015-08-13 |
| Pyrimidine derivatives Grant 9,006,241 - Hogberg , et al. April 14, 2 | 2015-04-14 |
| Pyrimidine derivatives Grant 8,927,547 - Hogberg , et al. January 6, 2 | 2015-01-06 |
| Novel Pyrimidine Derivatives App 20140045845 - Hogberg; Marita ; et al. | 2014-02-13 |
| Novel Pyrimidine Derivatives App 20130089518 - Hogberg; Marita ; et al. | 2013-04-11 |
| Acyclic Nucleoside Derivatives App 20120123119 - ENGELHARDT; Per ; et al. | 2012-05-17 |
| Acyclic nucleoside derivatives Grant 8,124,609 - Engelhardt , et al. February 28, 2 | 2012-02-28 |
| Indentification Of Compounds That Inhibit Replication Of Human Immunodeficiency Virus App 20090170953 - Balzarini; Jan Maria ; et al. | 2009-07-02 |
| Acyclic Nucleoside Derivatives App 20090076041 - ENGELHARDT; Per ; et al. | 2009-03-19 |
| Acyclic nucleoside derivatives Grant 7,432,274 - Engelhardt , et al. October 7, 2 | 2008-10-07 |
| Compounds That Inhibit Replication Of Human Immunodeficiency Virus App 20080076824 - Balzarini; Jan Maria Rene ; et al. | 2008-03-27 |
| Novel process and intermediates 085 App 20070270487 - Hedberg; Martin ; et al. | 2007-11-22 |
| Antivirals Grant 7,148,243 - Sahlberg , et al. December 12, 2 | 2006-12-12 |
| Identification of compounds that inhibit replication of human immunodeficiency virus App 20060188920 - Balzarini; Jan Maria Rene ; et al. | 2006-08-24 |
| Identification of compounds that inhibit replication of human immunodeficiency virus App 20060183748 - Balzarini; Jan Maria Rene ; et al. | 2006-08-17 |
| Identification of compounds that inhibit replication of human immunodeficiency virus App 20050096319 - Balzarini, Jan Maria Rene ; et al. | 2005-05-05 |
| Identification of compounds that inhibit replication of human immunodeficiency virus App 20040180893 - Balzarini, Jan Maria Rene ; et al. | 2004-09-16 |
| Acyclic nucleoside derivatives App 20040132749 - Engelhardt, Per ; et al. | 2004-07-08 |
| Acyclic nucleoside derivatives Grant 6,703,394 - Engelhardt , et al. March 9, 2 | 2004-03-09 |
| Antivirals App 20030119881 - Salhberg, Christer ; et al. | 2003-06-26 |
| Acyclic nucleoside derivatives App 20020188125 - Engelhardt, Per ; et al. | 2002-12-12 |
| Acyclic nucleoside derivatives Grant 5,869,493 - Engelhardt , et al. February 9, 1 | 1999-02-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 